Biogen Q1 2026 results demonstrate a significant advancement in the company’s “New Biogen” transformation, marked by a 2% year-over-year revenue increase and a major strategic acquisition. The company reported total revenue of $2.5 billion for the first quarter, driven by a 12% growth in its new product portfolio.
Financial Performance Overview
The company’s bottom line showed substantial strength during this period. GAAP diluted EPS rose by 31% to $2.15, while Non-GAAP diluted EPS reached $3.57, an 18% increase compared to the previous year.
Q1 2026 Revenue by Category
| Revenue Source | Q1 2026 (Millions) | Year-Over-Year Change |
| Total Revenue | $2,478 | 2% |
| Multiple Sclerosis (MS) | $958 | 0% |
| Rare Disease | $557 | (1)% |
| Alzheimer’s Collaboration | $60 | 80% |
| Anti-CD20 Programs | $419 | 11% |
Learn More: AstraZeneca Q1 2026 Results: Strong 8% Growth and Clinical Breakthroughs
Strategic Growth and the Apellis Acquisition
A cornerstone of the Biogen Q1 2026 results announcement was the proposed acquisition of Apellis Pharmaceuticals. This transaction is designed to:
- Add commercialized medicines in immune-mediated retinal disease and nephrology.
- Deepen the foundation for Biogen’s growing nephrology franchise, specifically supporting the Phase 3 asset felzartamab.
- Materially increase the Non-GAAP diluted EPS compounded annual growth rate through 2030.
Clinical Data and Pipeline Milestones
Biogen continues to underscore the potential of its registrational pipeline with new data across several key programs.
Key Clinical Program Updates
| Program | Indication | Highlights/Data Point |
| Litifilimab | Cutaneous Lupus Erythematosus (CLE) | Second positive Phase 2 dataset; meaningful reduction of disease activity at Week 16. |
| Salanersen | Spinal Muscular Atrophy (SMA) | Unprecedented new motor milestones in children with suboptimal status after gene therapy. |
| LEQEMBI | Alzheimer’s Disease | Real-world persistence data showed ~78% of patients remained on therapy at 18 months. |
| SPINRAZA | SMA | High Dose Regimen approved by the U.S. FDA. |
Kura Oncology and Kyowa Kirin Announce Groundbreaking Kyowa Kirin Ziftomenib Frontline AML Data for EHA 2026 Congress
Kura Oncology and Kyowa Kirin announced updated frontline data for ziftomenib combined with 7+3 chemotherapy in newly diagnosed NPM1-m and KMT2A-r AML patients, demonstrating high […]
GSK and Spero Therapeutics Secure Historic Utebzi FDA Approval for Adults with Complicated Urinary Tract Infections
The historic Utebzi FDA approval introduces the first and only oral carbapenem antibiotic for adult patients suffering from complicated urinary tract infections (cUTIs), offering an […]
Novo Nordisk Cyber Attack: Threat Group Demands $25 Million Ransom Following Massive Data Breach
Following a rejected $25 million extortion attempt, a cybercriminal group claims to have stolen 1.3 terabytes of sensitive data in a sophisticated Novo Nordisk cyber […]
Updated Full Year 2026 Guidance
Following the Biogen Q1 2026 results, the company has adjusted its financial outlook for the year.
- Non-GAAP Diluted EPS: Now expected to be between $14.25 and $15.25.
- IPR&D Impact: The guidance includes a $1.00 impact from acquired In-Process Research and Development (IPR&D) charges, largely driven by the TJ Biopharma agreement for felzartamab rights in Greater China.
- Total Revenue: Anticipated to decline by a mid-single digit percentage versus 2025.
